The estimated Net Worth of David Maki is at least $409 Tausend dollars as of 15 June 2015. Mr Maki owns over 72,750 units of Pulmatrix Inc stock worth over $409,114 and over the last 9 years he sold PULM stock worth over $0.
Mr has made over 1 trades of the Pulmatrix Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 72,750 units of PULM stock worth $500,520 on 15 June 2015.
The largest trade he's ever made was buying 72,750 units of Pulmatrix Inc stock on 15 June 2015 worth over $500,520. On average, Mr trades about 72,750 units every 0 days since 2015. As of 15 June 2015 he still owns at least 218,194 units of Pulmatrix Inc stock.
You can see the complete history of Mr Maki stock trades at the bottom of the page.
David J. Maki J.D. is the Advisor at Pulmatrix Inc.
Mr D is 63, he's been the Advisor of Pulmatrix Inc since . There are 5 older and 10 younger executives at Pulmatrix Inc. The oldest executive at Pulmatrix Inc is Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD, 72, who is the Founder & Member of Scientific Advisory Board.
David's mailing address filed with the SEC is C/O PULMATRIX, INC, 990 HAYDEN AVE, LEXINGTON, MA, 02421.
Over the last 9 years, insiders at Pulmatrix Inc have traded over $4,537,500 worth of Pulmatrix Inc stock and bought 290,998 units worth $2,002,066 . The most active insiders traders include Steven Gillis, Terrance Mcguire und Innovative Sciences, Inc. O.... On average, Pulmatrix Inc executives and independent directors trade stock every 92 days with the average trade being worth of $521,728. The most recent stock trade was executed by David L. Hava on 20 March 2017, trading 2,263 units of PULM stock currently worth $5,001.
pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. the platform, called isperse (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. the isperse powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance.
Pulmatrix Inc executives and other stock owners filed with the SEC include: